ArticleFrontiers in gastroenterology (Lausanne, Switzerland)2024

The continuing value of mesalazine as first-line therapy for patients with moderately active ulcerative colitis.

Kristine Paridaens et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.